Recent outbreaks of the Lassa Hemorrhagic Fever in Africa show vital need
for new products that can be processed in any clinical or field lab
DENVER, July 10 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an expansion of the collaborative effort for developing test kits for viral hemorrhagic fever (VHF) detection.
The viral products are being produced under a grant awarded by the National Institutes of Health (NIH) and were developed by Corgenix in collaboration with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), BioFactura, Inc., Autoimmune Technologies, LLC and various partners in West Africa.
Joining the collaboration is Vybion, Inc., an Ithaca, N.Y., based biotechnology company. Vybion CEO Lee Henderson, Ph.D., stated, "We are pleased to be able to work with Corgenix, Tulane and the other partners. With our deep experience in protein expression from bacterial and mammalian cells and our extensive technology portfolio, we will be able to provide the commercial scale-up for the recombinant protein efforts."
"The addition of Vybion to our group is an important step in achieving full commercialization of the products developed under this collaboration," said Douglass Simpson, Corgenix President and CEO. "We already have products in the field in Africa, and with Vybion's capabilities in producing large quantities of the critical reagents, we have the supply chain necessary for full scale production of these critically important detection products."
Corgenix and the other partners have developed and applied for a patent
for new recombinant proteins for Lassa virus. Lassa fever, a serious viral
infection spread by contact with infected rodents, is estimated to infect
300,000 to 500,000 people per year across West Africa, with approximately
5,000 deaths. Current tests ar
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved